

Top 20 Series-Rank 8-Jubilant with its growth story

14 October 2015 | Features | By BioSpectrum Bureau

Top 20 Series-Rank 8-Jubilant with its growth story



Organization: Jubilant Life Sciences

Co-chairman & MD: Hari S Bhartia

Revenue (Vaccines): Rs 483 crore

While its growth has been primarily driven by the generic pharmaceutical businesses, the Jubilant Life Sciences is also betting big on contract research. Jubilant Life Sciences is an integrated global pharmaceutical and lifesciences company engaged in manufacturing and supply of APIs, generics, specialty pharmaceuticals and lifescience ingredients. It also provides services in contract manufacturing and drug discovery and development.

The company's strength lies in its unique offerings of pharmaceutical and lifesciences products and services across the value chain. With 10 worldclass manufacturing facilities in India, US and Canada and a team of over 6,300 multicultural people across the globe, the company is committed to deliver value to its customers spread across 98 countries. The company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and lifesciences companies globally.

"Sustained strong performance in our radiopharmaceuticals business and normalization of CMO operations supported revenue growth in the pharmaceuticals segment. Going forward, we expect the pharmaceuticals segment to drive revenue growth with improvement in profitability in key businesses across both segments," mentioned Mr Shyam S Bhartia, chairman and managing director and

Mr Hari S Bhartia, co-chairman and managing director, Jubilant Life Sciences, adding further, "We also expect the management consolidation to drive the businesses in a focused manner to improve the operating performance. We will also continue our endeavors to strengthen the balance sheet."

The growth trend in pharmaceuticals products continued to be strong during the year. Generics saw benefit from new

launches in multiple regions as well as marketshare gains in existing products supported by integrated in-house API operations.

While specialty pharma gained with the launch of products in multiple geographies, growth in CMO business was due to better utilization of capacities. There have been total of 620 filings for formulations of which 167 have been approved in various regions of the world including 58 ANDAs in US and 41 Dossier filings in the Europe. Similarly, the company has a total API product pipeline of 235 filings across regions including 65 DMFs in US and 29 CEPs in Europe. The company has managed to resolve the FDA warnings issued in Montreal (Canada) and also remediation measures in Spokane (US).

Company expects to normalize its CMO business during the FY 2015-16. As per company, the strategy of new product launches and geographic expansion will continue to drive growth.